OncoPharm
John Bossaer
Add to My Podcasts
Episodes
About
Reviews
Promote
To Rechallenge, Or Not To Rechallenge
14 minutes
Posted Oct 17, 2019 at 7:55 pm.
0:00
14:32
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Weighing the risks & benefits of immunotherapy rechallenge in patients with a prior immune-related adverse event (irAE). Reference: https://www.ncbi.nlm.nih.gov/pubmed/31461381
Previous
CASPIAN
Next
ADAM VTE & Ibrutinib CV Toxicity
← See all 273 episodes of OncoPharm